Company intelligence / Profile preview

RevDoc

Ownership: Private
Development stage: Commercial

Overview

RevDoc is an active digital health and concierge medicine provider offering on-demand house calls, telemedicine, mobile clinics for urgent care and wellness—including weight loss medications like semaglutide—plus aesthetic procedures such as botox and laser therapy. The company operates via a membership model with direct-to-consumer pricing that bypasses insurance. Clinical results per se are not published since it is a healthcare delivery platform rather than a drug developer.

Therapeutic areas: OtherEndocrinologyDermatology
Modalities: Small moleculeBiologicDeviceNon-pharmacological therapy
Industry: Non-Academic Healthcare

Drug pipeline

1 asset

semaglutide

Commercial

Indications: Obesity, Weight management

Partnerships

No major pharmaceutical or biotech partnerships disclosed.

Beyond the preview

Go deeper on RevDoc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RevDoc.

Explore the full profile